AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04698564
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Trial: NCT00055471
Drug: ZD4054 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg oral tablets once daily
Trial: NCT00055471
Drug: ZD4054 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg + 2 x 2.5 mg oral tablets once daily
Trial: NCT00055471
Drug: ZD4054 22.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg + 2 x 2.5 mg oral tablets once daily
Trial: NCT04613895
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
Trial: NCT04613895
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Trial: NCT04401527
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of Normal Saline
Trial: NCT02787070
Drug: PQ supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02787070
Drug: PQ unsupervised
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03366155
Drug: FUDR-Dex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
Trial: NCT03366155
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
Trial: NCT01931202
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
Trial: NCT01724320
Drug: OTX008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
Trial: NCT00028730
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00947765
Drug: Local corticosteroid injection
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
Trial: NCT01571297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given subcutaneously for 35 days
Trial: NCT02524106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00818675
Drug: Comparator: Blinded Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
Trial: NCT00227656
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
Trial: NCT03959228
Drug: keto-analogs
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
Trial: NCT00043121
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00043121
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00043121
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03955380
Drug: Contraloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of capsules, drug substance or placebo without any exipients.
Trial: NCT02182960
Drug: Ibuprofen syrup
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03041805
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin may be used after procedure by the decision of the doctor
Trial: NCT00729365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
Trial: NCT00729365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo.
Trial: NCT02547233
Drug: LEO 43204 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02547233
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02175342
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02175342
Drug: Tiotropium-18 lactose powder
RxNorm normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02175342
Drug: Placebo lactose powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03334916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20mL TID
Trial: NCT02537067
Drug: CHONDRON
RxNorm normalized name: Chondrus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Trial: NCT03755700
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
Trial: NCT03755700
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Trial: NCT00529568
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blind matched placebo control daily oral administration
Trial: NCT03600883
Drug: Anti PD-1/L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous (IV) infusion
Trial: NCT01596673
Drug: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
RxNorm normalized name: Hydrocodone Bitartrate Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet.
Trial: NCT01596673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
Trial: NCT00217971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04138888
Drug: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Trial: NCT04138888
Drug: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Trial: NCT00255801
Drug: Targretin® (bexarotene)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255801
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02017379
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02017379
Drug: Metoclopromide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02112812
Drug: Eradication therapy for H.pylori infection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
Trial: NCT02112812
Drug: Eradication of Helcobacter Pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
Trial: NCT02112812
Drug: Eradication therapy for Helicobacter pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000512
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
Trial: NCT01472809
Drug: ZYGK1
RxNorm normalized name: Zygomycin K1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved
Trial: NCT03387592
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg/m2
Trial: NCT03387592
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m2
Trial: NCT01472809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
Trial: NCT01743807
Drug: GNKG168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168.
Trial: NCT04036227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution with the same composition to match active drug
Trial: NCT03435640
Drug: NKTR-262
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.
Trial: NCT00619086
Drug: Dexamethason Helvepharm ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Dexamethason i.v. 45 minutes prior to surgery
Trial: NCT00619086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml sodium chloride i.v. 45 minutes prior to surgery
Trial: NCT03005379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule-delivered placebo
Trial: NCT02165566
Drug: Regular-insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Trial: NCT04221087
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar water based on same ml dosing of intervention arm drug
Trial: NCT05222243
Drug: Direct pulp capping with calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
Trial: NCT05222243
Drug: Direct pulp capping with MTA
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capping exposed dental pulps during cavity preparation in primary teeth with MTA
Trial: NCT03891953
Drug: DKY709
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel immunomodulatory agent
Trial: NCT03891953
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
Trial: NCT01935869
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01812889
Drug: TOL-463 Vaginal ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL-463 Vaginal Ovule
Trial: NCT04246801
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Trial: NCT04401748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT03038178
Drug: LAI plus multi-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Trial: NCT02595528
Drug: AGN-199201 ophthalmic solution
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Trial: NCT02595528
Drug: AGN-190584 ophthalmic solution
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
Trial: NCT02595528
Drug: AGN-190584 vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle to AGN-190584
Trial: NCT02595528
Drug: AGN-199201 + AGN-190584 Combination
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
Trial: NCT02595528
Drug: AGN-199201 vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle to AGN-199201
Trial: NCT00237328
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin will be used as the intra-operative anticoagulant
Trial: NCT00833547
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Trial: NCT01690520
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04165330
Drug: AL3818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle.
Trial: NCT00096382
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenously over 1 hour
Trial: NCT00929812
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml NaCl 0.9% intramuscularly
Trial: NCT04468659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion.
Trial: NCT05504317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive corresponding dose of placebo injection subcutaneously.
Trial: NCT02133521
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Trial: NCT02133521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Trial: NCT03396393
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT02236754
Drug: 18 F-FP-DTBZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
Trial: NCT03182920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04351191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care plus placebo
Trial: NCT02343133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02858856
Drug: Sipjeondaebo-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Herbal medicine which is a compound of 10 herbs.
Trial: NCT03273127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abediterol matching placebo without any pharmacological activity.
Trial: NCT00865982
Drug: Docetaxel, Cisplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks.
Trial: NCT04146220
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
Trial: NCT02784860
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
Trial: NCT02667496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT00955279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
Trial: NCT00961753
Drug: optimized ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
Trial: NCT04411628
Drug: LY3819253
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.